Denver, CO – DaVita Inc. hosted its Q1 2024 Earnings Conference Call on May 2, 2024, at 5:00 PM ET. The call featured key company leaders such as Nic Eliason, Javier Rodriguez, and Joel Ackerman alongside several conference call participants such as Andrew Mok, Pito Chickering, and Kevin Fischbeck.

During the call, Nic Eliason, the Group Vice President of Investor Relations, highlighted the importance of forward-looking statements while discussing the company’s first-quarter performance. He emphasized the risks and uncertainties involved and provided details on non-GAAP financial measures. Additionally, Eliason mentioned the company’s focus on providing solutions for patients in various stages of the kidney care journey.

Javier Rodriguez, the CEO, followed with a discussion on the company’s first-quarter results, international business expansion, and efforts to address challenges in kidney transplants. Rodriguez also touched upon the company’s investment in expanding operations in Brazil, Colombia, Chile, and Ecuador. He highlighted the positive clinical outcomes in DaVita’s international markets and the company’s commitment to providing high-quality care.

Joel Ackerman, the CFO, provided detailed insights into the company’s financial performance and outlook. He discussed adjusted operating income, earnings per share, and free cash flow for the first quarter. Ackerman also addressed the impact of the Change Healthcare outage on the company’s balance sheet and financial metrics, reassuring investors that the operational impact was largely resolved.

Throughout the call, analysts raised questions about various aspects of DaVita’s business, including treatment volume growth, revenue per treatment, patient care costs, and center consolidations. The company executives responded with transparency and provided valuable insights into their strategies for continued growth and operational efficiency.

Overall, the Q1 earnings call highlighted DaVita’s strong performance, strategic initiatives for international expansion, and ongoing efforts to deliver clinical excellence in kidney care. The company remains focused on driving positive outcomes for patients while maintaining financial discipline and capitalizing on growth opportunities.